Seema Charitha Cheemala, Saif Syed, Ruqiya Bibi, Muawaz Bin Suhail, Mayankkumar D Dhakecha, Muhammad Subhan, Muhammad Shoaib Mahmood, Ahsan Shabbir, Hamza Islam, R. Islam
{"title":"Unraveling the Gut Microbiota: Key Insights into its Role in Gastrointestinal and Cardiovascular Health","authors":"Seema Charitha Cheemala, Saif Syed, Ruqiya Bibi, Muawaz Bin Suhail, Mayankkumar D Dhakecha, Muhammad Subhan, Muhammad Shoaib Mahmood, Ahsan Shabbir, Hamza Islam, R. Islam","doi":"10.9734/jammr/2024/v36i75483","DOIUrl":null,"url":null,"abstract":"The human gastrointestinal (GI) tract harbors a diverse and dynamic community of microorganisms known as the gut microbiome, which plays a fundamental role in maintaining gastrointestinal (GI) and cardiovascular health. It explores the intricate interplay between the gut microbiota, GI health, and cardiovascular diseases (CVDs). It discusses the essential roles of the gut microbiome in energy metabolism, nutrient absorption, immune regulation, and gut barrier integrity. Dysbiosis, characterized by an imbalance in gut microbiota composition, has been linked to various GI conditions, including inflammatory bowel diseases (IBD) and irritable bowel syndrome (IBS), as well as CVDs such as hypertension, atherosclerosis, and heart failure. Therapeutic strategies targeting the gut microbiome, including probiotics, prebiotics, fecal microbiota transplantation (FMT), and precision nutrition, offer promising avenues for managing GI and cardiovascular diseases. Recent research has brought attention to the significance of gut microbiota in CVDs, highlighting sex-specific variations, microbial metabolites' impact, and potential therapeutic interventions. Challenges in microbiome research, such as sample size limitations and methodological variability, are addressed, along with opportunities for innovation, including multi-omics integration and personalized medicine guided by microbiome data. By addressing these challenges and leveraging opportunities, gut microbiome research can revolutionize healthcare, ushering in a new era of personalized and microbiome-informed medicine. This comprehensive analysis offers valuable perspectives into the intricate relationship between gut microbiota, GI health, and cardiovascular diseases, paving the way for future research and clinical applications in this burgeoning field.","PeriodicalId":14869,"journal":{"name":"Journal of Advances in Medicine and Medical Research","volume":"24 6","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Advances in Medicine and Medical Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.9734/jammr/2024/v36i75483","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
The human gastrointestinal (GI) tract harbors a diverse and dynamic community of microorganisms known as the gut microbiome, which plays a fundamental role in maintaining gastrointestinal (GI) and cardiovascular health. It explores the intricate interplay between the gut microbiota, GI health, and cardiovascular diseases (CVDs). It discusses the essential roles of the gut microbiome in energy metabolism, nutrient absorption, immune regulation, and gut barrier integrity. Dysbiosis, characterized by an imbalance in gut microbiota composition, has been linked to various GI conditions, including inflammatory bowel diseases (IBD) and irritable bowel syndrome (IBS), as well as CVDs such as hypertension, atherosclerosis, and heart failure. Therapeutic strategies targeting the gut microbiome, including probiotics, prebiotics, fecal microbiota transplantation (FMT), and precision nutrition, offer promising avenues for managing GI and cardiovascular diseases. Recent research has brought attention to the significance of gut microbiota in CVDs, highlighting sex-specific variations, microbial metabolites' impact, and potential therapeutic interventions. Challenges in microbiome research, such as sample size limitations and methodological variability, are addressed, along with opportunities for innovation, including multi-omics integration and personalized medicine guided by microbiome data. By addressing these challenges and leveraging opportunities, gut microbiome research can revolutionize healthcare, ushering in a new era of personalized and microbiome-informed medicine. This comprehensive analysis offers valuable perspectives into the intricate relationship between gut microbiota, GI health, and cardiovascular diseases, paving the way for future research and clinical applications in this burgeoning field.